Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Other
- Industry
- Other
- ISIN
- USM201561018
- Market cap
- Not available
- P/E ratio
- Not available
- Analyst target
- 9
- Dividend yield
- 0.0%
- Beta
- Not available
- MarketCapitalization
- Not available
About
About Bioblast Pharma Ltd
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company has a collaboration with Team Sanfilippo to evaluate Trehalose for the treatment of sanfilippo syndrome. Bioblast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
Visit company website
No comments yet
Start a focused discussion about ORPN.